ISIN: CH0010532478 WKN: 936767 Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil / Basel, Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmetmedical needs.
27.12.2011 - 16:25:54ACTELION
Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland.
Veletri® (Epoprostenol for Injection) is a prostanoid vasodilator,indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Zavesca® (miglustat) is the first and only oral medication approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease, and it may only be used in those patients for whom enzyme replacement therapy is unsuitable.
Ventavis® (iloprost) is an inhaled formulation of iloprost, approved for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
The Company, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,200 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs.
Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI® )
Veletri® (Epoprostenol for Injection) is a prostanoid vasodilator,indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Zavesca® (miglustat) is the first and only oral medication approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease, and it may only be used in those patients for whom enzyme replacement therapy is unsuitable.
Ventavis® (iloprost) is an inhaled formulation of iloprost, approved for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
The Company, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,200 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs.
Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI® )
